Incyte (INCY) Profit Margin History
Historical gross, operating and net quarterly profit margin for Incyte (INCY) over the last 10 years. The current net profit margin for Incyte as of November 17, 2017 is -10.9%.
|Medical||Medical - Biomedical and Genetics||$22.258B||$1.106B|
|Incyte Corp is a drug discovery company that is using its expertise in genomics, medicinal chemistry and molecular, cellular and in vivo biology to discover and develop novel therapeutics. The company has three fully-staffed drug discovery programs underway focused primarily on the identification of new small molecule drugs for cancer and inflammation. Incyte also has strategic alliances with Lexicon Genetics and Medarex focused on the discovery and development of protein therapeutics or antibodies to treat inflammatory diseases and cancer.|